Format

Send to

Choose Destination
Pediatr Pulmonol. 2019 Sep 10. doi: 10.1002/ppul.24512. [Epub ahead of print]

Survey of current treatment practices for venous thromboembolism in patients with cystic fibrosis.

Author information

1
Department of Pharmacy, University of Utah Health, Salt Lake City, Utah.
2
Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah.

Abstract

BACKGROUND:

Patients with cystic fibrosis (CF) and venous thromboembolism (VTE) pose therapeutic challenges including potential drug interactions between CF-related therapies and anticoagulants. Despite these challenges, there are no recommendations for VTE management specific to patients with CF. Our objective was to describe VTE treatment practices among Cystic Fibrosis Foundation (CFF)-accredited care centers and affiliate programs in the United States.

METHODS:

An online survey was distributed to CF center directors. The survey included questions regarding centers' demographics and posed a series of hypothetical clinical scenarios to gather centers' VTE treatment practices including choice of anticoagulant, dosing practices, duration decisions, and monitoring efforts. Descriptive statistics were utilized to summarize the survey results.

RESULTS:

The survey response rate was 56.3%. Most centers reported treating zero to five VTE episodes per year. The following anticoagulants were used most often for VTE treatment: low-molecular-weight heparin (LMWH) (73.2%), apixaban (36.6%), warfarin (35.2%), rivaroxaban (33.8%), and unfractionated heparin (18.3%). On a scale of 0 to 100, the median confidence level in managing anticoagulant therapy was 50. Many centers expressed a desire for a CF-specific VTE treatment guideline. The most commonly cited challenging clinical situations were managing anticoagulant therapy complications (26.5%) and drug-drug interactions (21.3%). For common VTE scenarios, pediatric patients were most often treated with LMWH and warfarin, whereas adult patients were more often treated with apixaban or rivaroxaban.

CONCLUSIONS:

Survey results indicated CF care centers find managing VTE in patients with CF challenging and indicated that a CF-specific VTE treatment guideline would be helpful.

KEYWORDS:

anticoagulant; cystic fibrosis; survey; venous thromboembolism

PMID:
31502767
DOI:
10.1002/ppul.24512

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center